^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)

i
Other names: RRM2, Ribonucleotide Reductase Regulatory Subunit M2, Ribonucleoside-Diphosphate Reductase Subunit M2, Ribonucleotide Reductase M2 Polypeptide, Ribonucleotide Reductase Small Subunit, Ribonucleotide Reductase Small Chain, RR2, Chromosome 2 Open Reading Frame 48, Uncharacterized Protein C2orf48, FLJ25102, C2orf48, RR2M, R2
9d
Integrative single-cell transcriptomic and multi-dimensional bioinformatic analysis reveals proliferation-associated gene expression signatures and cellular heterogeneity in hepatocellular carcinoma. (PubMed, Discov Oncol)
This integrative multi-scale analysis reveals complex proliferation-associated gene expression patterns and substantial cellular heterogeneity within hepatocellular carcinoma. STMN1 and RRM2 emerge as dominant markers of proliferative reprogramming and promising candidate therapeutic targets warranting further functional investigation in HCC progression.
Journal
|
AURKA (Aurora kinase A) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • FANCD2 (FA Complementation Group D2) • STMN1 (Stathmin 1)
14d
Molecular Insights Into Canine Hepatocellular Carcinoma: A Cross-Species Transcriptomic Comparison With Human HCC. (PubMed, Mol Carcinog)
Based on human HCC data, SPP1, NQO1, RRM2, APOA1, APOC3, ALDOB, and IGF1 were identified as prognosticators indicating poor overall survival. This study presents the first cross-species transcriptomic analysis of canine HCC, revealing significant molecular resemblances to human HCC, indicating it may be a promising comparative model for studying tumor biology, drug responses, and novel therapeutic interventions.
Journal
|
SPP1 (Secreted Phosphoprotein 1) • IGF1 (Insulin-like growth factor 1) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • APOA1 (Apolipoprotein A-I) • ACTG1 (Actin Gamma 1) • ANXA5 (Annexin A5) • C1QB (Complement C1q B Chain)
19d
Logic-Gated HSV-TK/GCV Suicide Gene Circuit for Triple-Negative Breast Cancer. (PubMed, Adv Sci (Weinh))
The herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) suicide gene therapy system has shown promise in cancer treatment, but its clinical applicability is limited by off-target cytotoxicity...In two orthotopic breast cancer models, BRAS significantly suppressed tumor growth without affecting body weight or general health, underscoring its therapeutic potential. This approach intelligently combines molecular signals from both cancerous and healthy cells to precisely regulate therapeutic gene expression, making it a promising platform for the next-generation cancer therapy.
Journal
|
RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
1m
Regulation of ferroptosis in colorectal cancer through therapeutic modulation and miRNA targeting. (PubMed, Biochem Biophys Rep)
Interestingly, we also found that medications such as prasterone, tazemetostat, isoxyl, gemcitabine, ponsegromab, scx-2023, and nicotinamide could potentially be used in combination with the identified miRNAs to target ferroptosis in CRC. To further validate the stability and reliability of the predicted protein-ligand interactions, molecular dynamics (MD) simulations and MM-PBSA analyses were performed on selected top-ranking complexes, which confirmed their stable and favorable binding and supported the robustness of our docking results. These findings suggest that targeting these miRNAs and their associated genes, along with using the identified drugs, could be a promising strategy for CRC treatment, leveraging the potential of ferroptosis-inducing therapies.
Journal • PARP Biomarker
|
PARP1 (Poly(ADP-Ribose) Polymerase 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • SLC7A11 (Solute Carrier Family 7 Member 11) • MIR16 (MicroRNA 16) • MIR15A (MicroRNA 15a) • MIR423 (MicroRNA 423) • MIR93 (MicroRNA 93)
|
gemcitabine • Tazverik (tazemetostat) • ponsegromab (PF-06946860)
2ms
Identification of a Musashi2 translocation as a novel oncogene in myeloid leukemia. (PubMed, Elife)
Although Gleevec has been transformative for CML, blast crisis CML remains relatively drug resistant...These data suggest that MSI2-HOXA9 acts, at least in part, by increasing expression of the mitochondrial polymerase POLRMT and augmenting mitochondrial function and basal respiration in blast crisis. Collectively, our findings demonstrate for the first time that translocations involving the stem and developmental signal MSI2 can be oncogenic and suggest that MSI, which we found to be a frequent partner for an array of translocations, could also be a driver mutation across solid cancers.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • HOXA9 (Homeobox A9) • RRM1 (Ribonucleotide Reductase Catalytic Subunit M1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • MSI2 (Musashi RNA Binding Protein 2)
|
imatinib
2ms
Integrative high-throughput studies to develop novel targets and drugs for the treatment of advanced prostate cancer. (PubMed, Genes Dis)
These agents exhibited superior anti-tumor efficacy compared with AR antagonists in vitro. Our study identified novel prostate cancer therapeutic targets independent of the AR signaling pathway and established a research paradigm for developing anti-tumor agents through integrative cancer bioinformatics and network pharmacology analysis.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CDC20 (Cell Division Cycle 20) • E2F1 (E2F transcription factor 1)
2ms
Network-based insights into miR-30a-5p-mediated regulation and EGCG targeting in triple-negative breast cancer. (PubMed, Front Bioinform)
The results emphasizes that EGCG has strong binding affinity towards YWHAZ, revealing that miR-30a-EGCG targets TNBC synergistically through cell-cycle-mediated pathways. The findings give rational support for miRNA-guided phytochemical-based TNBC therapeutic development.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • PCNA (Proliferating cell nuclear antigen) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • ANLN (Anillin Actin Binding Protein) • CCNA1 (Cyclin A1) • MIR30A (MicroRNA 30a) • SKP2 (S-phase kinase-associated protein 2) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta)
|
HER-2 expression
2ms
Integrating multi-omics data and machine learning to identify endocrine disrupting chemicals targeting key ccRCC-related genes. (PubMed, Discov Oncol)
This analysis identified 8 EDCs potentially involved in ccRCC: Diethylnitrosamine, Diethylstilbestrol, Resveratrol, 4,4'-diaminodiphenylmethane, Trichloroethylene, Arsenic, Lead, and 2,3,5-(triglutathion-S-yl)hydroquinone...Furthermore, cell-cell communication analysis revealed distinct signaling patterns among EDC-associated subpopulations, offering new insights into how EDCs may modulate gene expression and contribute to ccRCC progression. This study provides a foundation for future investigations into EDC-driven tumor biology and may guide the development of targeted therapies and preventative strategies against ccRCC.
Journal
|
CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • BIRC5 (Baculoviral IAP repeat containing 5) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • TRIB3 (Tribbles Pseudokinase 3)
2ms
Integrated transcriptomic and single-cell analysis reveals cell cycle dysregulation and cellular heterogeneity in lung cancer. (PubMed, Discov Oncol)
This integrated multi-omics approach reveals the complex transcriptional landscape and cellular heterogeneity in lung cancer.
Journal
|
AURKA (Aurora kinase A) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • FANCD2 (FA Complementation Group D2) • STMN1 (Stathmin 1)
2ms
ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer. (PubMed, Cell Death Dis)
This ENO1-mediated aggregation of RRM2 protein increases the synthesis of dNTPs in pancreatic cancer cells, enhancing the resistance of pancreatic cancer to gemcitabine. Our study reveals a role of ENO1 in pancreatic cancer via RRM2-STUB1 axis and provides a scientific basis for the development of new therapeutic strategies targeting ENO1.
Journal
|
ENO1 (Enolase 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
gemcitabine
2ms
Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer. (PubMed, Sci Rep)
This study demonstrates that unsupervised clustering combined with WGCNA and ML enables the discovery of clinically relevant molecular signatures in PCa. Our findings establish TPX2-centered networks together with biological pathways implicated in mitotic regulation and DNA damage repair as key drivers of tumor evolution, providing a biologically informed source for biomarker development, drug testing and mechanistic studies.
Journal
|
PLK1 (Polo Like Kinase 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • MYBL2 (MYB Proto-Oncogene Like 2) • NEIL3 (Nei Like DNA Glycosylase 3) • CENPA (Centromere protein A)